{"as_of":"2026-08-12T03:54:00Z","caps":{"database_statements":6,"inbound":100,"outbound":100},"context_digest":"sha256:80ea5c5518e140dbdedbd3795f3d36b2de0924a46e24eb637eb3ed7d0987e6bd","coverage":[{"denominator":81,"lane":"reference_resolution","note":"Typed states for the displayed outbound observations.","records_observed":81,"source":"paper_references, paper_reference_links","source_observed_at":"2026-08-10T20:22:00.646949Z","state":"measured"},{"denominator":81,"lane":"standing_notices","note":"One-hop event checks from named stored sources.","records_observed":81,"source":"scholarly_work_events, retraction_status_cache","source_observed_at":"2026-08-11T06:34:44.6726+00:00","state":"measured"},{"denominator":0,"lane":"inbound_itemization","note":"Pith citing papers itemized under the disclosed page cap.","records_observed":0,"source":"paper_references, paper_reference_links","source_observed_at":null,"state":"measured"},{"denominator":1,"lane":"external_citation_measurements","note":"A source-named dated measurement, never combined with another source.","records_observed":0,"source":"cited_works","source_observed_at":null,"state":"measured"}],"external_citation_measurements":[],"inbound":[],"links":{"evidence":"/evidence","html":"/paper/2501.08744/citation-record","integrity":"/paper/2501.08744/integrity","json":"/paper/2501.08744/citation-record.json","paper":"/paper/2501.08744"},"outbound":[{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:01.736995Z","title":null,"venue":null,"work_id":"b6a9d351-5e87-4e26-a97e-bcb5fe406164","year":null},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":1,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.393878Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:4d001207726603cdb25a092c4a0bb501a2de9d5c45294f91d597cf4f94d6d396","observation_id":"d563f134-2bf1-40d2-9394-83463f20a8a6","resolution":{"observed_at":"2026-08-10T20:22:01.740946Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:01.724870Z","title":"This common/pooled RTE is assigned a vague normal prior distribution, ~ (0,1000)dN","venue":null,"work_id":"b1f050a1-b2f9-49d0-af28-8db194c5e99e","year":null},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":2,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.397661Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:9d535fd90548a8b0fe06b976c366bc1d110018c385f9c91b5d42596eabc114d3","observation_id":"f224a5b4-9d3e-48fb-b748-df200357e96e","resolution":{"observed_at":"2026-08-10T20:22:01.729326Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:01.713358Z","title":"The pooled parameter dm is assigned a vague normal prior distribution and a weakly informative half-normal prior distribution is assigned to the standard deviation, d","venue":null,"work_id":"d2ed37c4-7e09-4551-a4cb-4987c7b79bcb","year":2003},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":3,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.401515Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:6f87379212a3e315b7e9f9e49b4ba3b1408e469bbae5a158a78f913f2179ea07","observation_id":"c9f65e27-d52a-4e76-ae54-148af1c0c2b4","resolution":{"observed_at":"2026-08-10T20:22:01.717485Z","resolver_source":"raw_fallback","status":"malformed_identifier"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1200/jco.2010.28.0982","metadata_source":"doi_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:00.816398Z","title":null,"venue":null,"work_id":"b92c6f60-8c67-4654-8b96-b2af6ee79e85","year":2011},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":4,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.417639Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:aeba886133ecbde461aeab7ec01e61a5ace238f690a9fdde7bb2d0b3dce77fad","observation_id":"bbe61f6f-7cfa-434d-bf15-02c280f4f470","resolution":{"observed_at":"2026-08-10T20:22:00.819844Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1200/jco.2010.34.1255","metadata_source":"doi_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:00.805865Z","title":null,"venue":null,"work_id":"3da77614-12b8-4e70-958f-d1e8ad04d651","year":2011},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":5,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.421413Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:13c0826af2b6a625caa932a7f9f8b4fdeb6bfc5fa9dc2f82fe3a41a730c4be6f","observation_id":"506868eb-6d7f-45c1-a854-e1bf862890d9","resolution":{"observed_at":"2026-08-10T20:22:00.809145Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1200/jco.2008.21.6457","metadata_source":"doi_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:00.795547Z","title":null,"venue":null,"work_id":"e2aad9e4-1d60-4d66-9d3e-7ada842d02c8","year":2010},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":6,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.425199Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:d40406fac54e12d3943697ab6ce728614611c62eb4b9ad2c0b0c94917ee698d3","observation_id":"94fcd6f2-f4c6-4e27-b2cc-aca4363f8e75","resolution":{"observed_at":"2026-08-10T20:22:00.798852Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1038/bjc.2013.69","metadata_source":"doi_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:00.783554Z","title":"Biomarker results from the A V ADO phase 3 trial of first- line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer","venue":null,"work_id":"c62cb30c-c0b6-46f4-b9de-9faa7ba41c4e","year":2013},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":7,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.429124Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:871d6334c2adab15b15206c80042e4813a0b4f69033e0de3ee21ae9931f0d891","observation_id":"a54fecb0-d673-4a41-8f8f-a090da3d302a","resolution":{"observed_at":"2026-08-10T20:22:00.788297Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1200/jco.2012.44.7912","metadata_source":"doi_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:00.772312Z","title":null,"venue":null,"work_id":"f5b9c2da-d06f-4e39-8243-0c66967b1b70","year":2013},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":8,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.432840Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:9f4be0bf51f0fdc847a2479788072898739baee950235c7818f3f5665fa4307c","observation_id":"143ca053-4a17-4750-afc9-d03c3a850c33","resolution":{"observed_at":"2026-08-10T20:22:00.775893Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1016/j.clbc.2011.03.005","metadata_source":"doi_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:00.760189Z","title":"Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: A phase III, randomized, open-label trial","venue":null,"work_id":"d18ad8ec-2a63-4238-8b55-e88f29854d0b","year":2011},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":9,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.437102Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:45eade015b7de382225b66ff9ca5d5cab3fd15b8e96db9a24c53ff247c17ab3b","observation_id":"87451710-3c93-48e9-a476-a087dfe8620c","resolution":{"observed_at":"2026-08-10T20:22:00.764936Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[{"edge_observation":{"observed_at":"2026-08-11T06:34:47.152789+00:00","source":"paper_reference_links","state":"open"},"event_date":"2011-08-03","event_type":"correction","notice_doi":"10.1016/j.clbc.2011.06.004","provenance":{"observed_at":"2026-07-11T03:12:43.466735+00:00","source":"crossref","source_record_id":"10.1016/j.clbc.2011.06.004->10.1016/j.clbc.2011.03.005:correction"}}],"reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1016/s1470-2045(11)70037-7","metadata_source":"doi_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:00.748196Z","title":null,"venue":null,"work_id":"d5351f33-d231-4912-86fd-4e0a729c5bad","year":2011},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":10,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.440852Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:1fd5d0b355e9354ad06c8219780ac829ddf1eb5ca274fbd886fbb73f5b08f92f","observation_id":"9d1dd3bd-82b6-4e0d-9192-5535340d2e35","resolution":{"observed_at":"2026-08-10T20:22:00.752191Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[{"edge_observation":{"observed_at":"2026-08-11T06:34:47.619194+00:00","source":"paper_reference_links","state":"open"},"event_date":"2011-08-02","event_type":"correction","notice_doi":"10.1016/s1470-2045(11)70205-4","provenance":{"observed_at":"2026-07-11T03:17:45.890087+00:00","source":"crossref","source_record_id":"10.1016/s1470-2045(11)70205-4->10.1016/s1470-2045(11)70037-7:correction"}}],"reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1200/jco.2014.57.2388","metadata_source":"doi_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:00.735122Z","title":"Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study","venue":null,"work_id":"522899dc-5944-42bd-9a10-a132f4dbd6d0","year":2015},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":11,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.444960Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:5582b6f51669bd76141a8045d9b57625f910e306aaf931266105d349ebbb4060","observation_id":"6f697f93-70e5-471f-8553-a5cf184f4d02","resolution":{"observed_at":"2026-08-10T20:22:00.740392Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1200/jco.2012.30.15_suppl.605","metadata_source":"doi_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:00.723445Z","title":null,"venue":null,"work_id":"554cb34e-b9bc-47fd-9e8b-4f69714b8f75","year":2012},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":12,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.448740Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:f072edbfdf23bc7ca2a64c1b3a3f707bb790e18b905877c7028ce4a453a9137c","observation_id":"b9496b2c-7590-4ce3-b56b-81b8fb34790e","resolution":{"observed_at":"2026-08-10T20:22:00.727640Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:01.702170Z","title":null,"venue":null,"work_id":"81f87b76-3c17-4580-b217-da219ba9bc4e","year":2007},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":13,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.452440Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:64c533500490d493baceae6f7dbc83c99429604eb4e2418aec30a58690c0b741","observation_id":"bbbc6bec-fd8f-4fd1-bd12-86f9f0c7c851","resolution":{"observed_at":"2026-08-10T20:22:01.705821Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1093/annonc/mdw316","metadata_source":"doi_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:01.476883Z","title":null,"venue":null,"work_id":"baf8a123-bb0e-4638-b24f-744503ef3841","year":2016},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":15,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.459986Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:a9be7a5ceb24a57ed9daf4f044a57dfbbdb930964682ef42528774cd63bc25cf","observation_id":"474d4a03-f840-4833-b3eb-dd68048ef2d1","resolution":{"observed_at":"2026-08-10T20:22:01.480166Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1016/j.ejca.2016.09.024","metadata_source":"doi_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:01.466593Z","title":null,"venue":null,"work_id":"03db101c-91fe-41c0-8657-f50d0903ac2b","year":2017},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":16,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.463385Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:6efbdbc4b1c3bd145a1dcecc3ce021db888565ce0616eacf8207669a8803e1ea","observation_id":"465b5e09-69a4-473b-8ba3-14daaa64c38e","resolution":{"observed_at":"2026-08-10T20:22:01.470146Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1056/nejmoa1309748","metadata_source":"doi_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:01.455042Z","title":"Improved survival with bevacizumab in advanced cervical cancer","venue":null,"work_id":"7cd31c3f-cdc5-44b0-95cd-79e41b41fda8","year":2014},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":17,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.467135Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:2672c4f65e54022d29ee3f38be43af01dcf96ee263404cbb8857700d74e2a5b3","observation_id":"27263ccb-c647-441d-afa1-ffb4a141c66c","resolution":{"observed_at":"2026-08-10T20:22:01.458992Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":null,"pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:00.470736Z","title":null,"venue":null,"work_id":null,"year":2017},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":18,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.470736Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:5155f9779704ab0ac79e8fd61fbb4d474ce3adc01e9bd5f653d180b516a00ffd","observation_id":"1407a4fc-3044-4d94-ab6b-aebd6342f4c8","resolution":{"observed_at":"2026-08-10T20:22:00.470736Z","resolver_source":null,"status":"malformed_identifier"},"standing_notice":{"events":[],"reason":"canonical_work_link_unavailable","source_receipts":[],"state":"unavailable"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1200/jco.2003.10.066","metadata_source":"doi_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:01.430798Z","title":"Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer","venue":null,"work_id":"d607cd4b-0474-4afb-85b9-e2d7db6844f5","year":2003},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":19,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.474470Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:88c168472162f37cc239d769d4886ba60146943d85d844e473912ff54a90bd6b","observation_id":"533af837-8f09-45a4-b438-976ac6f9079a","resolution":{"observed_at":"2026-08-10T20:22:01.435165Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1200/jco.2005.05.112","metadata_source":"doi_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:01.418800Z","title":"Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial","venue":null,"work_id":"c6b8f46a-785e-40dd-901f-ebc07c101f3d","year":2005},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":20,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.477936Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:cf2cdad4dd8ebd7563d2d1ee2c80b75e0ee781b7c1d69bf9ee0e6c189fe1b716","observation_id":"284b8049-3ffd-4983-b9bf-6456fd30bf58","resolution":{"observed_at":"2026-08-10T20:22:01.422927Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1056/nejmoa032691","metadata_source":"doi_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:01.406800Z","title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","venue":null,"work_id":"377b8016-142d-4a5d-a8a8-f820a82b2089","year":2004},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":21,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.481450Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:4fb290e4330e83aa17c6e9275e4f07f2925c39740d9b86c6900eb33e0252f5d2","observation_id":"80402f93-7729-4943-929d-409aa314679a","resolution":{"observed_at":"2026-08-10T20:22:01.411108Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1200/jco.2006.09.6305","metadata_source":"doi_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:01.394988Z","title":null,"venue":null,"work_id":"b4f8bc2b-f1cb-44de-8607-6c25b99d4c78","year":2007},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":22,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.484988Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:62f76d5c7aaeff455c7f1e264e55095d5de8b65227128279c6cb86190795bcff","observation_id":"c5f8d6fa-cd0a-4845-a2d9-f3333b95ac2e","resolution":{"observed_at":"2026-08-10T20:22:01.398942Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1200/jco.2007.14.9930","metadata_source":"doi_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:01.383309Z","title":"Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study","venue":null,"work_id":"f4b25902-0356-450c-b421-81c62b988eb2","year":2008},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":23,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.488666Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:a41956a2d9d10bd9620934c84e726ef439962a3305bd79eb4f194c39084c72f9","observation_id":"fd9b26fd-c938-4242-92f6-1d928678583f","resolution":{"observed_at":"2026-08-10T20:22:01.387409Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1038/bjc.2011.201","metadata_source":"doi_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:01.372231Z","title":"XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results","venue":null,"work_id":"0895dcf9-e3ec-43e8-b8bb-dadc1e456fc0","year":2011},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":24,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.491921Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:4531c1a63276dc71432e06839e9f2807b5e0be10f683a723796ef9eaca9d8788","observation_id":"72d62f28-fdcf-426a-bbb3-314dc3c6fc47","resolution":{"observed_at":"2026-08-10T20:22:01.376226Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1200/jco.2009.27.7723","metadata_source":"doi_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:01.360774Z","title":null,"venue":null,"work_id":"49f9260b-7973-41e4-976f-3a89705b7508","year":2010},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":25,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.495623Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:d0efe0de9e4a21d35ecccdf0e287d1e73951715515f50457b9ed6bd66f0db056","observation_id":"af7c4c0d-f3fa-41bf-892a-ca58036b134c","resolution":{"observed_at":"2026-08-10T20:22:01.364431Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1016/s1470-2045(12)70477-1","metadata_source":"doi_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:01.349008Z","title":"Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial","venue":null,"work_id":"764510d1-a782-4063-845c-175a758d9cd9","year":2013},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":26,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.499083Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:343ff02cc33308a7bac74273af2dfcf922e0770351cef4129c9e2854f4c9b6f2","observation_id":"d35ee039-2697-48f3-97f9-a500496bf647","resolution":{"observed_at":"2026-08-10T20:22:01.353252Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1093/annonc/mdt231","metadata_source":"doi_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:01.337123Z","title":null,"venue":null,"work_id":"f9112c24-a349-4926-9133-8c3cef374e03","year":2013},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":27,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.502674Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:a6ddaab08af2da3a0272a38cd5330d947e7e4ec5508b73af7a8622012f5b058e","observation_id":"2c14b25d-0d11-42c7-80ee-6eb35ebe0f30","resolution":{"observed_at":"2026-08-10T20:22:01.341235Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1200/jco.2012.42.5355","metadata_source":"doi_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:01.324495Z","title":null,"venue":null,"work_id":"651d37bc-1c04-4604-9b91-a70a33dc22bf","year":2012},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":28,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.506496Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:34f9caf452882823174a007516fa58f33e10acd8e102051fba5132f7050f3284","observation_id":"503a9aa2-042b-4635-a4f8-315c7c964705","resolution":{"observed_at":"2026-08-10T20:22:01.328360Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":null,"pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:00.510334Z","title":"Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (A VEX): an open- label, randomised phase 3 trial","venue":null,"work_id":null,"year":2013},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":29,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.510334Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:32099a53f11353aa32a93d45c60ca75d135fba7f4027e1d166cc35aaf8499b12","observation_id":"ce23734f-6a3a-4d04-b299-df57f6fab278","resolution":{"observed_at":"2026-08-10T20:22:00.510334Z","resolver_source":null,"status":"malformed_identifier"},"standing_notice":{"events":[],"reason":"canonical_work_link_unavailable","source_receipts":[],"state":"unavailable"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.5732/cjc.011.10188","metadata_source":"doi_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:01.299019Z","title":"Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial","venue":null,"work_id":"cd0ca86d-fbe1-471b-9ba2-d31849f6f729","year":2011},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":30,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.513821Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:6fae280ade9adc8419d5294ffd5e7362ddcfc01cf93ff26f2d3ebc9e390d0113","observation_id":"4436beaf-1826-46bb-ad37-16f525ee1a2e","resolution":{"observed_at":"2026-08-10T20:22:01.304038Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1056/nejmoa1308573","metadata_source":"doi_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:01.287153Z","title":"A randomized trial of bevacizumab for newly diagnosed glioblastoma","venue":null,"work_id":"59c5c24c-9cdf-4e4f-b7ff-1911fba5076e","year":2014},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":31,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.517598Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:a1d715fc212ff05aa1c1ed917ad79471597d4f6b2661b5792c488e9e96638e4d","observation_id":"b29e1c59-31e5-4e6b-b151-a635a5b01bf9","resolution":{"observed_at":"2026-08-10T20:22:01.290827Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1200/jco.2015.61.5005","metadata_source":"doi_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:01.275780Z","title":null,"venue":null,"work_id":"af00b12e-1aff-4728-a087-c22a784d5686","year":2015},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":32,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.521363Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:b802bda9c1620ac2be527161f5d1b326fe8e9c66c4ae129a95d2158683579e43","observation_id":"f9a61b50-a85c-4b6b-a991-4785d12c50ac","resolution":{"observed_at":"2026-08-10T20:22:01.279531Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[{"edge_observation":{"observed_at":"2026-08-11T00:18:03.633065+00:00","source":"paper_reference_links","state":"open"},"event_date":"2016-08-24","event_type":"correction","notice_doi":"10.1200/jco.2016.69.6674","provenance":{"observed_at":"2026-07-11T02:56:59.531935+00:00","source":"crossref","source_record_id":"10.1200/jco.2016.69.6674->10.1200/jco.2015.61.5005:correction"}}],"reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1200/jco.2016.34.15_suppl.2001","metadata_source":"doi_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:01.262729Z","title":"EORTC 26101 phase III trial exploring the combination of bevacizumab and lomustine in patients with first progression of a glioblastoma","venue":null,"work_id":"5ac1ba3a-ba33-4eda-98d1-868b0f468c7c","year":2016},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":33,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.525180Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:12ca795b8bed72c6c254e92b4fee90f6d820a9a9ec8aa61001764e2322ea297b","observation_id":"25f584ae-1d8f-4b3e-b1f3-5b769a6ca016","resolution":{"observed_at":"2026-08-10T20:22:01.267282Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1056/nejmoa061884","metadata_source":"doi_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:01.251363Z","title":"Paclitaxel-carboplatin alone or with bevacizumab for non- small-cell lung cancer","venue":null,"work_id":"df5b7a6d-f16d-425e-815c-7f8e6fbdca54","year":2006},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":34,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.528692Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:82495c745cd6a958d5e7f3ae97166cd17049bf296f24dd574e46297321ba5eea","observation_id":"63fe323d-f90a-46c5-bbee-e3a5af8d7ff5","resolution":{"observed_at":"2026-08-10T20:22:01.255140Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1200/jco.2007.14.5466","metadata_source":"doi_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:01.237065Z","title":"Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: A V Ail","venue":null,"work_id":"e9950633-fb7d-49ca-bb4b-582301dab044","year":2009},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":35,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.533005Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:a314261d5536bbe0b83ab99d17dcccefe5c389a265bf03d339cdcf82a2d005c8","observation_id":"93b97b06-da19-4836-9341-25c4c268ce99","resolution":{"observed_at":"2026-08-10T20:22:01.241749Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1093/annonc/mdq020","metadata_source":"doi_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:01.224919Z","title":null,"venue":null,"work_id":"10b58136-13ad-494b-af56-d162d0797151","year":2010},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":36,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.536585Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:a17ac3902a1e80fc07e2bd4da3699065fda6bf2deaeaf7e5c58fc829fff8367f","observation_id":"b8f00e9e-18d2-4c3f-bcb3-bb928ff2e6ab","resolution":{"observed_at":"2026-08-10T20:22:01.229113Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:01.691103Z","title":null,"venue":null,"work_id":"eeeebdf6-6712-4182-886d-e348057b9046","year":2014},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":37,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.540124Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:89bea29936de54a6aa6630537c35a96d407c353090c4d45b9cc9d846cdd70d8e","observation_id":"f540eeca-2a6b-4cc6-b7fd-11ee4932a229","resolution":{"observed_at":"2026-08-10T20:22:01.694912Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1016/j.lungcan.2020.11.020","metadata_source":"doi_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:01.197889Z","title":null,"venue":null,"work_id":"cb715827-f266-4328-8a03-d5326064b989","year":2021},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":38,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.548044Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:bdcbe584b69d2865d36252ca3cf6f74be58122c421abad556f98e4c7a24c108f","observation_id":"2926a412-04ab-4879-a995-4edd77895682","resolution":{"observed_at":"2026-08-10T20:22:01.203106Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1200/jco.2014.59.4424","metadata_source":"doi_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:01.182015Z","title":null,"venue":null,"work_id":"f0d54037-8562-421a-808a-1a99d01ffdf3","year":2015},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":39,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.551713Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:d0148220d001d5c4bb0a08d71eb8e12d675efa3c6dbdbb2c08af4428b6d062aa","observation_id":"774cf3c2-e4d8-47d6-bac6-45bbeee8a6c3","resolution":{"observed_at":"2026-08-10T20:22:01.187316Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:01.680138Z","title":null,"venue":null,"work_id":"9014c7ad-7e7d-42bf-b896-852a7e190def","year":2019},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":40,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.555364Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:b34985eee43ff0fb489b65248d51b77b89f2d30072042de41115a94cb636a857","observation_id":"73b713b3-4080-4e17-adbe-57867d61ffba","resolution":{"observed_at":"2026-08-10T20:22:01.683931Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1016/j.jtho.2021.07.009","metadata_source":"doi_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:01.158323Z","title":"IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC","venue":null,"work_id":"8607a721-314b-4269-9f53-57d1e00006f3","year":2021},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":41,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.563158Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:41bd7db0558a500af145fcc77c49260f42aebc88be9cb43ab3df48fe13aa2700","observation_id":"ffb3556a-8fe8-42e7-8034-bfe68b561cb5","resolution":{"observed_at":"2026-08-10T20:22:01.163658Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1016/s1470-2045(19)30035-x","metadata_source":"doi_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:01.133325Z","title":null,"venue":null,"work_id":"d0de636b-f628-49d1-b611-b0b8a7e3d9a7","year":2019},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":42,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.566457Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:2ada00c457804d78e7e153684d50d08db056615513ff660260457fa7a252dc62","observation_id":"80f9434f-ab1e-4159-8f28-a3783ce6be75","resolution":{"observed_at":"2026-08-10T20:22:01.138049Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1016/s2213-2600(21)00166-1","metadata_source":"doi_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:00.691635Z","title":null,"venue":null,"work_id":"e6d23119-6452-40d7-aebb-ddfd43fbb96d","year":2022},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":43,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.569466Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:c086ecb7a185003218d642b1396e6e2861c9fb27a65515f6eb0c66ea0c1981b2","observation_id":"e5ab4c71-72ac-4a72-8229-1bece14f149a","resolution":{"observed_at":"2026-08-10T20:22:00.695676Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1056/nejmoa1104390","metadata_source":"doi_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:01.102166Z","title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","venue":null,"work_id":"d9b88a7a-22d1-4ecc-8775-2eb48cfe9ac5","year":2011},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":44,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.572456Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:556ceb2e2d59906f424214cae510d3e104d06bbe1565f9e1c38cce5d7752c2ba","observation_id":"ef0672ab-8495-461f-adc8-c136e06276e0","resolution":{"observed_at":"2026-08-10T20:22:01.107182Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1200/jco.19.01009","metadata_source":"doi_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:01.086227Z","title":"Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer","venue":null,"work_id":"59c1e3fb-9f94-428e-a8b9-8d5e5b243669","year":2019},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":45,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.575341Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:bc22acfaeae1c898b8d0acefeada31948dcbe869bb1d06871d97a94271293be8","observation_id":"a0ff79dc-c504-4599-8309-9d105b722830","resolution":{"observed_at":"2026-08-10T20:22:01.090622Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1056/nejmoa1103799","metadata_source":"doi_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:01.071934Z","title":"A phase 3 trial of bevacizumab in ovarian cancer","venue":null,"work_id":"4353118c-bf25-49e1-b586-f2a531ec5a95","year":2011},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":46,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.578249Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:d5d6ecbfb2f21addae8801f772252381262df16fffae77f75955817cf36b6361","observation_id":"beb30c89-3aec-46f7-b928-c0739a6fccec","resolution":{"observed_at":"2026-08-10T20:22:01.077249Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1016/s1470-2045(15)00086-8","metadata_source":"doi_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:01.052315Z","title":"Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): Overall survival results of a phase 3 randomised trial","venue":null,"work_id":"08d84fcd-ad9a-48e2-833b-eef2a545d88d","year":2015},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":47,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.581548Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:2dbdcbc94c1d60513116722e9be9f22e5f4e5b8585e388585e10dcf60ad02ba5","observation_id":"33fdf2ed-9e25-4640-8fa7-5ecc9119333f","resolution":{"observed_at":"2026-08-10T20:22:01.056962Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1200/jco.2012.42.0505","metadata_source":"doi_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:01.039101Z","title":null,"venue":null,"work_id":"90658e78-bf2b-4295-9120-3454305d2e5e","year":2012},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":48,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.584354Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:551c5f65476f7fdb78a89eea1c061a959cd14dd262eed29eafba44605a2781d8","observation_id":"616b779f-11da-44c7-9eec-f9f141a740a4","resolution":{"observed_at":"2026-08-10T20:22:01.043126Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1016/j.ygyno.2015.08.004","metadata_source":"doi_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:01.024933Z","title":"Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer","venue":null,"work_id":"28c95754-a7b0-414b-a810-959642ac701b","year":2015},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":49,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.587526Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:67aa281e1f0bcf5d8983ab2d8631faa5ed8a49cd8889df9641e0a11080f3da00","observation_id":"2fe6f5c1-7d67-43c8-9f06-35d13417f996","resolution":{"observed_at":"2026-08-10T20:22:01.029087Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1016/s1470-2045(17)30279-6","metadata_source":"doi_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:00.677705Z","title":null,"venue":null,"work_id":"a8a1b7f7-6f62-4c06-8d41-34fb9b1cfaba","year":2017},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":50,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.590311Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:cad73a17778f65e06aff9e43e5e9358206936caa3531f6f3814ac83e81518f8b","observation_id":"5d682c8c-2b78-4e9e-a0f7-6fba75ffd206","resolution":{"observed_at":"2026-08-10T20:22:00.682714Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1200/jco.2013.51.4489","metadata_source":"doi_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:01.005621Z","title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial","venue":null,"work_id":"1dce8354-c578-4a4f-94e1-188c1580ffd9","year":2014},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":51,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.593626Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:4cd5233127b3634dc3f75d8e4a0028488fce82679ff15ac69de2f2f74a5c1007","observation_id":"eeedaa85-d612-4ac4-a05e-4883d1678511","resolution":{"observed_at":"2026-08-10T20:22:01.009857Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1093/annonc/mdx228","metadata_source":"doi_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:00.993927Z","title":"Bevacizumab with or after chemotherapy for platinum- resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial","venue":null,"work_id":"3c7047be-f1ca-4677-b656-1764b92865cf","year":2017},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":52,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.596683Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:7d0ee6c8eed0a87c7be1a25e86c0b05e10ba358415292bb581e0d8668fe14428","observation_id":"40d45e4e-65b4-4903-96f4-d292fa73c85c","resolution":{"observed_at":"2026-08-10T20:22:00.998021Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1016/j.ygyno.2019.03.256","metadata_source":"doi_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:00.982889Z","title":null,"venue":null,"work_id":"880c8057-0fc2-4fa6-810f-225a61f7a891","year":2019},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":53,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.599646Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:5e1865b244bde6d69a9d73191a8f434008b1ccbf3abaaaa0320707bdc1f57857","observation_id":"afc67627-1073-45a6-980b-ed0a984e9212","resolution":{"observed_at":"2026-08-10T20:22:00.986892Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1056/nejmoa021491","metadata_source":"doi_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:00.971512Z","title":"A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer","venue":null,"work_id":"c798c1b7-62d3-4583-b8c9-f4f24885d01c","year":2003},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":54,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.602952Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:8b6f8e07171e53622c5df4cafb8687e93c79d17522e880b3860f80d9ec65ab2a","observation_id":"99c06af9-c50d-4fe4-b96a-461b67d8c5fe","resolution":{"observed_at":"2026-08-10T20:22:00.975600Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1016/s1470-2045(14)70439-5","metadata_source":"doi_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:01.487714Z","title":null,"venue":null,"work_id":"bd6d9bff-aeaa-4d2c-8115-604b550a13c5","year":2014},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":55,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.170206Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:8286b15c5ad88cc529138ac21604042a218302e173007e4d3833ddc889defee7","observation_id":"4155ebfc-98c7-49d2-88f3-efaf3b2552f9","resolution":{"observed_at":"2026-08-10T20:22:01.491748Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1016/s0140-6736(17)31607-0","metadata_source":"doi_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:01.443151Z","title":"Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)","venue":null,"work_id":"d7fd05cd-98e7-4c9a-b868-21a153894e32","year":2017},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":59,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.189211Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:ddce5362fce798010ce5ed9587c0ac8462b9f484d46aea518db0eba57f0ef860","observation_id":"98904ff8-be65-4106-9cab-a44af26949c0","resolution":{"observed_at":"2026-08-10T20:22:01.447499Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":null,"pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:00.202876Z","title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","venue":null,"work_id":null,"year":2004},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":62,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.202876Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:9287a8e183fbc57fc6dc0a08c6d09ddadacc44dfeaea9b2ce95ace8a8326ea39","observation_id":"873f2042-e766-4a01-94ad-d376fc5d8c72","resolution":{"observed_at":"2026-08-10T20:22:00.202876Z","resolver_source":null,"status":"unresolved"},"standing_notice":{"events":[],"reason":"canonical_work_link_unavailable","source_receipts":[],"state":"unavailable"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1016/s1470-2045(13)70154-2","metadata_source":"doi_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:01.312045Z","title":"Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (A VEX): an open-label, randomised phase 3 trial","venue":null,"work_id":"ead074f3-c1be-4152-aa9d-645e0a475dd3","year":2013},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":70,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.240808Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:45ed2c2fa950063d9ef9af4d15b2864a26d94e9490d4232fc131e7d9c919de58","observation_id":"3988e2f6-8d43-4544-ab6b-865cc525d2de","resolution":{"observed_at":"2026-08-10T20:22:01.316275Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:01.770010Z","title":null,"venue":null,"work_id":"79d961fb-3351-4b35-ba9c-839103bbb601","year":2015},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":73,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.252930Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:897de3e8c4b4b7bb5b2c5299d4088818cb977cb5e2254f7f3bf8cfc38bece4d1","observation_id":"6155dce0-8e60-4668-9e94-4a399fe45688","resolution":{"observed_at":"2026-08-10T20:22:01.773693Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":null,"pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:00.289765Z","title":null,"venue":null,"work_id":null,"year":2019},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":81,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.289765Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:5ea2700880fb7cd4c6c1c388319e3c57357b8fff8969e6e2b187a7154eb1916f","observation_id":"409297a9-ee90-49c3-a43a-9435ddd42f80","resolution":{"observed_at":"2026-08-10T20:22:00.289765Z","resolver_source":null,"status":"malformed_identifier"},"standing_notice":{"events":[],"reason":"canonical_work_link_unavailable","source_receipts":[],"state":"unavailable"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1016/s2213-2600(21)00166-","metadata_source":"doi_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:01.117754Z","title":null,"venue":null,"work_id":"270470ad-030c-4d38-b257-cf70c1a7cd10","year":2022},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":84,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.301707Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:32398ba678c792fd1927ab647dac663ea80e30a971088da5134b213d04daad6c","observation_id":"1fe2a228-e35e-48a7-a1b6-228b852bcee0","resolution":{"observed_at":"2026-08-10T20:22:01.122158Z","resolver_source":"doi_truncated","status":"malformed_identifier"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:01.759014Z","title":"Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced 30 Urothelial Carcinoma: Results of CALGB 90601 (Alliance)","venue":null,"work_id":"78fd5cb2-c90f-4f18-bfe2-df9aeaaab5d9","year":2021},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":103,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.375895Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:9f4a3087419ff3845ad8b58c8dc52b30375c582f22bea79458a5d8c6915ebc87","observation_id":"a3b6001f-9cb2-4c88-889c-c53a7b012590","resolution":{"observed_at":"2026-08-10T20:22:01.763297Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:01.748035Z","title":"On weakly informative prior distributions for the heterogeneity parameter in Bayesian random‐effects meta‐analysis","venue":null,"work_id":"d82c708d-ac59-44d1-bbbf-99e4d5494436","year":2005},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":106,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.389258Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:bf0ad8c51afe134dd0b0211db78de631e2c7471811028dcf4c2d26673f9b1583","observation_id":"e085776d-211b-479e-9a2b-7b079a9ecc99","resolution":{"observed_at":"2026-08-10T20:22:01.751966Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1200/jco.2005.05.098","metadata_source":"doi_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:00.852727Z","title":"Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer","venue":null,"work_id":"f1f8e498-55d4-4813-917c-58f2fdaade27","year":2005},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":107,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.406266Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:255e1b0869adaf0f893403258edf7750c272dffcdb2334fd67af817bd1e6a642","observation_id":"82774529-ebd5-4a9a-a670-533aef9986c1","resolution":{"observed_at":"2026-08-10T20:22:00.856845Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1056/nejmoa072113","metadata_source":"doi_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:00.840112Z","title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","venue":null,"work_id":"10a2d901-5f44-4956-a6cb-18841c0db2eb","year":2007},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":108,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.410045Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:53d00a1703632e7b22db10818b002a1612cb651a58580877b67c52e390cf4a80","observation_id":"8dd591cd-be97-4c42-9f78-465907be9623","resolution":{"observed_at":"2026-08-10T20:22:00.844662Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1016/s1359-6349(08)70289-1","metadata_source":"doi_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:00.826999Z","title":"Bevacizumab in the first-line treatment of metastatic breast cancer","venue":null,"work_id":"9cb9e747-968a-44a3-93d2-05afa8e46186","year":2008},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":109,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.413732Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:6c40bb3110e31852e06a7cdb174deea3c4013bb09a864eb9e7ab49f445fe1d8f","observation_id":"8606b344-9d2c-432e-bbc5-1b99b083846a","resolution":{"observed_at":"2026-08-10T20:22:00.831065Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1200/jco.2008.16.9847","metadata_source":"doi_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:00.959949Z","title":"Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206","venue":null,"work_id":"8a8bcdc8-90af-4b67-aadb-82c1fda443f7","year":2008},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":115,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.606253Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:84e80282d5df531d081ad0410a7fe22ebb484a497d79011386a312ce2a3399cc","observation_id":"0eb3da54-2e89-46f4-87d8-989b83003e47","resolution":{"observed_at":"2026-08-10T20:22:00.963962Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1200/jco.2009.26.5561","metadata_source":"doi_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:00.947788Z","title":"Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206","venue":null,"work_id":"6db449c1-3607-449d-8345-34ae09a645bf","year":2010},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":116,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.609256Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:ae7c7cf99e3fb28aadb45e6bd980ea80a7e8f898e5827dfc5c97c2a12d7b6e3b","observation_id":"34ec7524-e127-4126-a769-4aa6643018b3","resolution":{"observed_at":"2026-08-10T20:22:00.951885Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:01.668258Z","title":"Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial","venue":null,"work_id":"c28fd0f2-9356-4643-bc6d-d6dab6da89ed","year":2007},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":117,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.612286Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:6be43800114f524f113c001596afa62b076a7eb0b2f0a93f559ee39e33a00020","observation_id":"c609bc6f-6896-4855-8fd0-83b61b23c008","resolution":{"observed_at":"2026-08-10T20:22:01.672546Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1200/jco.2009.26.7849","metadata_source":"doi_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:00.923474Z","title":"Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (A VOREN): final analysis of overall survival","venue":null,"work_id":"51a59a4c-f31c-43b2-94f5-afccb95d4948","year":2010},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":119,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.618159Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:dfbfa40e93ed426d750b72011739b71c8bd493dbeea61d2db57d8c311b39baa9","observation_id":"17a47edf-fe0c-4c2c-9eed-69517b6d054a","resolution":{"observed_at":"2026-08-10T20:22:00.927619Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1007/s10120-014-0351-5","metadata_source":"doi_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:00.913177Z","title":null,"venue":null,"work_id":"422dfef2-ed1f-44b5-a4a6-6196f0739c4e","year":2015},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":120,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.621194Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:55f697134742a67c98c5aa53e620a5199acb386276595871213f7efa2a74389a","observation_id":"fb0f8d45-6448-4fa3-8ed4-ab5c18d1fbe6","resolution":{"observed_at":"2026-08-10T20:22:00.916610Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1200/jco.2011.36.2236","metadata_source":"doi_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:00.901776Z","title":"Bevacizumab in combination with chemotherapy as first- line therapy in advanced gastric cancer: A randomized, double-blind, placebo-controlled phase III study","venue":null,"work_id":"4d67d59c-89e8-4f0a-a3e6-8c2eeedbb8be","year":2011},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":121,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.623971Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:6a311bfdad52878df34b587af598eda601015f6a18baaa07e5dcaab9bee2a101","observation_id":"006bf548-801e-472d-ae2d-cfbb48b0664f","resolution":{"observed_at":"2026-08-10T20:22:00.905920Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":"2013.10081","doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:01.611173Z","title":"R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: Final MAIN study outcomes","venue":null,"work_id":"b3331cbf-4b2b-4424-b90d-78057e07f073","year":2014},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":122,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.626726Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:4e59ef58a3e540a27600e254be03018fc6a29500a95bf8d98494f91a8ea8c030","observation_id":"f7bf03a2-2a2e-4af2-86bc-b98ae90bef06","resolution":{"observed_at":"2026-08-10T20:22:01.618955Z","resolver_source":"raw_fallback","status":"metadata_mismatch"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1200/jco.21.00286","metadata_source":"doi_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:00.888019Z","title":"Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance)","venue":null,"work_id":"e1c030b6-d5bf-44eb-afe1-156e5050edcf","year":2021},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":123,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.630140Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:bd63b8069ffc3b4895190c8b32c48292885dab85184d0510fa5a003807b943a5","observation_id":"9e59c117-db0b-4037-8d00-0b0f55ad0109","resolution":{"observed_at":"2026-08-10T20:22:00.892970Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:01.656694Z","title":null,"venue":null,"work_id":"d863ed0c-8d91-405a-a4f3-247b199e1656","year":2012},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":124,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.633481Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:1ce86389c67f3f7441ee0310cd61c72c38b14e2a4d5cc46b8d57fe1bacdadacf","observation_id":"f7facc4d-9b14-44cc-8534-00e3fca312dc","resolution":{"observed_at":"2026-08-10T20:22:01.660315Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1200/jco.2014.58.3781","metadata_source":"doi_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:00.863989Z","title":null,"venue":null,"work_id":"0a78b7f9-9761-43f5-aa96-d47f05303031","year":2015},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":126,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.640113Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:ef20cc43b8d2c4d9b9f92194e36d7409fe551bbd99d539878b19c54f0bc96c41","observation_id":"711aa054-97f6-4458-9545-26827acdc170","resolution":{"observed_at":"2026-08-10T20:22:00.867601Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:01.644069Z","title":"Bayesian methods in meta-analysis and evidence synthesis","venue":null,"work_id":"82da3f47-54ff-44a5-b136-28dd61db145e","year":2001},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":127,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.643214Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:f5055b7d3ab721172097e282cd85459167d388b1ec1bb3e839d49643bfc47d9b","observation_id":"49b953c8-be43-4a58-99dc-37a67a51182d","resolution":{"observed_at":"2026-08-10T20:22:01.648786Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:01.628489Z","title":"On weakly informative prior distributions for the heterogeneity parameter in Bayesian random‐effects meta‐analysis","venue":null,"work_id":"c0f9ca09-7dc8-473c-b6e6-5ab7fb5919e7","year":2021},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":128,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.646949Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:10417ba765c60b0842cd2244db97f4d4191c6929ab09011cd6c69f83abb52ff7","observation_id":"f9d59e0e-422f-40cf-95d3-3da100260b59","resolution":{"observed_at":"2026-08-10T20:22:01.633009Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1016/s2213-2600(19)30084-0","metadata_source":"doi_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:00.704268Z","title":"DOI: 10.1016/s2213-2600(19)30084-0","venue":null,"work_id":"5e8721c6-4d7c-4c26-b4c2-6ca5b3b4df75","year":null},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":401,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.559041Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:02d4aba34937b164c140cf99256c72e113493e317743314e2141c1c107513296","observation_id":"69fe44ee-0d37-4f82-b583-06018e308e5b","resolution":{"observed_at":"2026-08-10T20:22:00.708404Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1016/s1470-2045(14)70381-x","metadata_source":"doi_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:01.211891Z","title":"DOI: 10.1016/s1470-2045(14)70381-x","venue":null,"work_id":"3e258847-6a64-4690-a6d1-d2f25fa133c6","year":null},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":1244,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.543875Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:d99c6e8f973e996a54947829b8fc617559ae465aae873aaf2379a2f3c3bd8ff2","observation_id":"373f3541-b6fb-4c7c-b492-59b2811c888f","resolution":{"observed_at":"2026-08-10T20:22:01.216069Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[{"edge_observation":{"observed_at":"2026-08-11T06:34:47.387766+00:00","source":"paper_reference_links","state":"open"},"event_date":"2014-09-30","event_type":"correction","notice_doi":"10.1016/s1470-2045(14)70506-6","provenance":{"observed_at":"2026-07-11T03:14:07.972603+00:00","source":"crossref","source_record_id":"10.1016/s1470-2045(14)70506-6->10.1016/s1470-2045(14)70381-x:correction"}}],"reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1200/jco.2011.39.4767","metadata_source":"doi_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:00.875500Z","title":null,"venue":null,"work_id":"a4000c3d-94c0-4a31-825f-317a08d0136f","year":2011},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":1540,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.636969Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:5c5bac9afb9eeb12e4a106c97d3a2b108311c0bfe509c1be8827724521cb12d6","observation_id":"3dba0e75-b4f3-4c49-a927-1623ca5480b0","resolution":{"observed_at":"2026-08-10T20:22:00.879637Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1016/s0140-6736(07)61904-7","metadata_source":"doi_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T20:22:00.934988Z","title":null,"venue":null,"work_id":"804eb4d7-ca5c-4c0e-b350-10e6710fcdbb","year":null},"citing_paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab","version":1},"reference_index":2111,"source":"pdf_text","source_observed_at":"2026-08-10T20:22:00.615105Z"},"links":{"citing_paper":"/paper/2501.08744"},"observation_digest":"sha256:1c37d9ad15b81fcd8faafa20c63f9b75cbd32165d10197bcb9fd90ddcb0771a7","observation_id":"bd52ef17-eb81-4ae2-aee2-23ffe933c46e","resolution":{"observed_at":"2026-08-10T20:22:00.939515Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"state":"measured"}}],"paper":{"arxiv_id":"2501.08744","last_updated":"2025-01-15T11:59:28Z","latest_version":1,"primary_category":"stat.AP","snapshot_observed_at":"2026-08-11T16:15:05.963466Z","submitted_at":"2025-01-15T11:59:28Z","title":"Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab"},"reference_resolution":{"displayed":81,"state_counts":{"malformed_identifier":5,"metadata_mismatch":1,"parse_uncertain":0,"unresolved":7,"verified_exact":62,"verified_fuzzy":6},"total_outbound_references":81},"refusal":"A citation records a reference. It does not transfer a finding from one paper to another.","schema":"pith.paper-citation-record.v1","standing_sources":[{"observed_at":"2026-08-11T06:34:44.6726+00:00","source":"crossref"},{"observed_at":"2026-08-11T06:34:36.301508+00:00","source":"retraction_watch"}],"thesis":"As of 12 August 2026, this Paper Citation Record lists 81 of 81 outbound references and 0 inbound Pith citation observations for arXiv:2501.08744."}